Cancer Precision Medicine Commons
2023 Activities Update
12.30.2023

The Cancer Precision Medicine Commons (Commons) hosted by LUNGevity Foundation, provides an opportunity for multi-stakeholder organization leaders to share information and resources aimed at advancing precision medicine for oncology patients, while identifying and collectively exploring opportunities for multi-stakeholder, cross-tumor collaborations that could engage activities through potential work groups. Information about the Commons can be found at cancerprecisionmedicinecommons.org.

Commons activities are guided by a small steering group:

Participating organizations include:



In 2023 the Commons met virtually for four quarterly, 90-minute sessions.

- The March 2023 Commons Q1 meeting provided an opportunity for members to learn about an ongoing, fully decentralized precision medicine trial for rare cancer patients led by TargetCancer Foundation (the TRACK study).
- The July 2023 Commons Q2 meeting featured a panel discussion focused on advancing use of precision medicine in community oncology settings.
- The September 2023 Commons Q3 meeting focused on the policy landscape for precision medicine.
- The December 2023 Q4 meeting offered an opportunity for Commons members to meet with industry partners for a discussion of shared priorities and cross-sector collaboration opportunities, including presentations from ACCC colleagues on their EMR integration and Precision Medicine Steward initiatives.

Additionally, three working groups (based on input from all Commons member organizations and industry partners who convened in December 2022) gathered multiple times throughout the year to define and develop deliverables aimed at advancing specific efforts. The three working groups comprised volunteers from among the Commons membership, and focused on the following topic areas and action plans:

Working Group on Consistent Testing Terminology:

Objective: Continue to disseminate consistent testing terminology for broader use.

Action Plan:

- Evaluate NCCN guidelines (clinical and patient-facing) for use of alternative terms to collect data (focus on Biomarker Testing).
- Develop a submission to NCCN for the Commons to send urging use of consistent terms.
- Leverage additional channels to educate key providers on recommended terms (reach out to ASCO, ACCC, CAP & AMP members).

Deliverables:

- The working group conducted an audit of NCCN clinical and patient-facing guidelines across multiple cancer types to evaluate variability in use of terms to describe biomarker testing (a similar audit for genetic testing for inherited cancer risk was not undertaken).

- Based on the audit, a letter to NCCN leadership with sign on from the vast majority of Commons organizations has been finalized and will be submitted in early 2024.

Working Group on Best Practice Tools for Patient Education Resources (biomarker testing and genetic testing for inherited risk)

Objective: Build on the Edge Research audit rubric to develop a best practices tool for patient advocacy group creation of patient-facing precision medicine educational resources.

Action Plan:

- Develop a template of best practice recommendations in key categories (one for Biomarker Testing & one for Genetic Testing for Inherited Risk).
- Provide recommendations for basic level of information and ones for savvier/higher health literacy patients/caregivers.
- Disseminate this resource widely among advocacy colleagues and eventually providers & industry partners.

Deliverables:

- The working group completed two rubrics to guide various stakeholders in their efforts to develop patient-facing education materials (one about biomarker testing and one about genetic testing for inherited cancer risk). These rubrics include checklists and detailed “do’s/don’ts. They can be downloaded at cancerprecisionmedicinecommons.org.

Rubrics: Checklists

Rubrics: Example Sections



Working Group on Access to Testing

Objective: Support policy efforts to address Utilization Management and other coverage/reimbursement barriers to access (especially among medically underserved).

Action Plan:

- Map the authorization pathway/coverage experience for testing.
- Develop narrative evidence to support ongoing policy efforts (federal/state), including stories from among WG members of barriers to access for testing (genetic and biomarker).
    - Develop a template to seek additional stories from among Commons member contacts (HCPs).

Deliverables:

- The working group has developed two insurance authorization barriers documents (one for biomarker testing and one for genetic testing for inherited cancer risk). These documents can be downloaded at cancerprecisionmedicinecommons.org.
- Two surveys of healthcare providers (including clinicians, advanced practitioners, and other members of the care team involved in ordering precision medicine testing) were fielded via Survey Monkey in Q4 of 2023. The surveys were designed to evaluate how often the various authorization barriers are encountered by healthcare providers and their impact on timely access to testing for patients. Approximately 90 responses were received for the biomarker testing survey and 60 responses for the genetic testing for inherited cancer risk survey. Survey results will be evaluated by the working group in early 2024 and then disseminated in a narrative report designed to support ongoing policy efforts to ensure access to appropriate testing.